Fri, February 4, 2022
Thu, February 3, 2022
Wed, February 2, 2022
Tue, February 1, 2022
Mon, January 31, 2022
Sun, January 30, 2022
Fri, January 28, 2022
Thu, January 27, 2022

Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $29 on, Feb 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-29-on-feb-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $47 to $29 on, Feb 1st, 2022.

Matthew has made no other calls on ADCT in the last 4 months.



There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Matthew


  • Andrew Galler of "Wolfe Research" Initiated at Buy and Held Target at $44 on, Tuesday, November 9th, 2021
  • Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Wednesday, November 3rd, 2021

Publication Contributing Sources